
Claims:

1. A method for producing a liquid pharmaceutical composition comprising a sodium salt of letermovir of formula (I)



(I)

or a solvate thereof at a concentration in the range of from 20 to 100 mg/mL with respect to Letermovir free base comprising the following steps:

i) providing a solution of a sodium salt of letermovir or a solvate thereof and at least one excipient selected from the group consisting of sucrose, mannitol, phenylalanine, a poloxamer, in particular poloxamer 188, and a polyvinylpyrrolidone (PVP), in particular PVP PF12, in a physiologically acceptable diluent, particularly a parenterally acceptable diluent, wherein said solution is essentially free from any additional buffer and any complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD);

ii) if needed adjusting the pH of the solution obtained in step i to a range of from 7 to 8 preferably with HCl;


iii) optionally filtering the obtained solution.

2. The method according to claim 1 wherein the sodium salt of letermovir is in the amorphous form or the solvate of the sodium salt of letermovir or is a crystalline monohydrate or a crystalline trihydrate.

3. The method according to claim 1 or 2, further comprising the subsequent additional step of freeze-drying the obtained solution to provide a lyophilizate.

4. The method according to claim 3 further comprising the step of reconstituting said lyophilizate in a parenterally acceptable diluent which is essentially free from complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD).

5. A liquid pharmaceutical composition comprising a sodium salt of letermovir of formula (I)



(I)

or a solvate thereof at a concentration in the range of from 20 to 100 mg/mL with respect to Letermovir free base and at least one excipient selected from the group consisting of sucrose, mannitol, phenylalanine, a poloxamer, in particular poloxamer 188, and a polyvinylpyrrolidone (PVP), in particular PVP PF12, dissolved in a physiologically acceptable diluent, particularly a parenterally acceptable diluent, wherein the liquid pharmaceutical composition is essentially free from complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD).

6. The liquid pharmaceutical composition according to claim 5 further comprising a polyalkoxy compound, in particular a poloxamer, more particular poloxamer 188, and is essentially free from other complexing solubilizing agents.

7. The liquid pharmaceutical composition according to claim 5 or 6, wherein the excipient is mannitol or sucrose or a combination thereof.

8. The liquid pharmaceutical composition according to any one of claims 5 to 7, further comprising a buffer, preferably Tris hydroxy aminomethane (Tris).


9. The liquid pharmaceutical composition according to any one of claims 5 to 8, further comprising HCl.

10. The liquid pharmaceutical composition according to any one of claims 5 to 9 having a pH in the range of from 7 to 8.

11. The liquid pharmaceutical composition according to any one of claims 5 to 10, which is obtainable by the method as defined in claim 1 or 2.

12. The liquid pharmaceutical composition according to any one of claims 5 to 11 which is suitable for oral application.

13. A solid pharmaceutical composition comprising a sodium salt of letermovir of formula (I)



(I)

or a solvate thereof and at least one excipient selected from the group consisting of sucrose, mannitol, phenylalanine, a poloxamer, in particular poloxamer 188, and a polyvinylpyrrolidone (PVP), in particular PVP PF12 , wherein said solid pharmaceutical composition

- is essentially free from complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD), and

- is capable of providing a solution when being dissolved in water without any additional buffer and without any additional complexing solubilizing agents selected from the group

consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD), wherein said solution

- comprises the sodium salt of letermovir or the solvate thereof at a concentration in the range of from 20 to 100 mg/mL with respect to letermovir free base and
- exhibits a pH in the range of from 7 to 8, preferably 7.4 to 7.8.

14. The solid pharmaceutical composition according to claim 13, wherein said excipient is sucrose or mannitol.

15. The solid pharmaceutical composition according to claim 13 or 14 which is a lyophilizate.

16. The solid pharmaceutical composition according to claim 15 obtainable by the method as defined in claim 3.

17. A liquid pharmaceutical composition according to claim 5 comprising the solid pharmaceutical composition as defined in any one of claims 13 to 16 dissolved in a first parenterally acceptable diluent which is essentially free from complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD).

18. The liquid pharmaceutical composition according to claim 17 diluted in a second parenterally acceptable diluent which is essentially free from complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD), to a concentration which is acceptable for intravenous (IV) injection or infusion, wherein said first and said second parenterally acceptable diluents can be identical or different from each other.

19. The liquid pharmaceutical composition according to claim 17 or 18 having a pH in the range of from 7 to 8.

20. The liquid pharmaceutical composition according to any one of claims 17 to 19 obtainable by the method as defined in claim 4.

21. The liquid pharmaceutical composition according to any one of claims 5 to 12, the solid pharmaceutical composition according to any one of claims 13 to 16 or the liquid

pharmaceutical composition according to any one of claims 17 to 20, having a stability in accordance with ICH Q1A (R2) covering climate zones I to IV.

22. The liquid pharmaceutical composition according to any one of claims 5 to 12 or 21, the solid pharmaceutical composition according to any one of claims 13 to 16 or 21 or the liquid pharmaceutical composition according to any one of claims 17 to 21 for use in a method of treatment and/or prevention of infection of herpes viridae group viruses, preferably human cytomegalovirus (HCMV).

23. Use of the liquid pharmaceutical composition according to any one of claims 5 to 12 or 21, the solid pharmaceutical composition according to any one of claims 13 to 16 or 21 or the liquid pharmaceutical composition according to any one of claims 17 to 21 in the manufacture of a medicament for the treatment and/or prevention of infection of herpes viridae group viruses, preferably human cytomegalovirus (HCMV).